Table 1. Proportion of subjects with ≥1 IU/L, ≥10 IU/L, ≥100 IU/L, and anti-HBs GMTs at different study time points.
| Time point | Group | Proportion of subjects with titres ≥1 mIU/ml | Proportion of subjects with titres ≥10 mIU/ml | Proportion of subjects with titres ≥100 mIU/ml | GMT IU/L |
|---|---|---|---|---|---|
| CI95% | CI95% | CI95% | CI95% | ||
| One month post-primary vaccination | Y5 | 100 | 100 | 98.5 | 3836 |
| 98.1-100.0 | 98.1-100.0 | 95.6-99.7 | 3071-4792 | ||
| Y10 | 100 | 100 | 99.5 | 4740 | |
| 98.0-100.0 | 98.0-100.0 | 97.0-100.0 | 3893-5772 | ||
| Y15 | 100 | 100 | 100 | 4171 | |
| 97.9-100.0 | 97.9-100.0 | 97.9-100.0 | 3441-5055 | ||
| Pre-booster | Y5 | 94.9 | 82.3 | 42.4 | 73 |
| 90.9-97.5 | 76.3-87.4 | 35.4-49.6 | 54-99 | ||
| Y10 | 95.2 | 86 | 47.3 | 89 | |
| 91.0-97.8 | 80.2-90.7 | 40.0-54.7 | 66-121 | ||
| Y15 | 86.9 | 68.2 | 29.5 | 28 | |
| 81.0-91.5 | 60.7-75.0 | 22.9-36.9 | 20-39 | ||
| One month post-booster | Y5 | 99.5 | 99.5 | 98.5 | 19544 |
| 97.2-100.0 | 97.2-100.0 | 95.6-99.7 | 13928-27426 | ||
| Y10 | 100 | 99.5 | 98.4 | 40754 | |
| 98.0-100.0 | 97.0-100.0 | 95.4-99.7 | 30853-53831 | ||
| Y15 | 100 | 99.4 | 97.7 | 11232 | |
| 97.9-100.0 | 96.9-100.0 | 94.3-99.4 | 8208-15369 | ||
| One year post-booster | Y5 | 100 | 99 | 91.4 | 3972 |
| 98.1-100.0 | 96.4-99.9 | 86.6-94.9 | 2810-5614 | ||
| Y10 | 100 | 99.5 | 93.5 | 4013 | |
| 98.0-100.0 | 97.0-100.0 | 89.0-96.6 | 3041-5296 | ||
| Five years post booster | Y5 | 100 | 97 | 85.9 | 1297 |
| 98.1-100.0 | 93.5-98.9 | 80.2-90.4 | 952-1768 | ||
| Y10 | 100 | 97.8 | 89.8 | 1423 | |
| 98.0-100.0 | 94.6-99.4 | 84.5-93.7 | 1078-1880 | ||
| Ten years post booster | Y5 | 98.5 | 94.9 | 76.3 | 453 |
| 95.6-99.7 | 90.9-97.5 | 69.7-82.0 | 332-618 |
Note : Y5-received a booster dose 5 years post-primary vaccination; Y10-received a booster dose 10 years post-primary vaccination; Y-15 received a booster dose 15 years post-primary vaccination.